TrialCancer research communications2022

A Phase II Study Investigating Cabozantinib in Patients with Refractory Metastatic Colorectal Cancer (AGICC 17CRC01).

Aaron J Scott et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.